Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Teijin: Bonalon to Spur Business in 2nd Half
November 25, 2002
- PRESS SEMINAR
November 25, 2002
- Kyowa Hakko: Drug Sales Down 0.6% to \71.4 Bil.
November 25, 2002
- DIAGNOSTICS NEWS IN BRIEF
November 25, 2002
- Torii: Sales in 1st Half Down 7.9%
November 25, 2002
- New Drug Organization to Properly Conduct Safety Surveillance: Dr Sakaguchi
November 25, 2002
- Nippon Shinyaku: Sales, Profitability Show Signs of Recovery
November 25, 2002
- EAD Director Urges Wholesalers to Eliminate Inappropriate Trade Practices: FJPWA Seminar
November 25, 2002
- Ono: Mainstays Contribute to Sales, Profits Growth
November 25, 2002
- NEW PRODUCTS
November 25, 2002
- Dainippon: Sales Up, Profits Remain at Low Levels
November 25, 2002
- WEBSITE NEWS
November 25, 2002
- Tanabe Seiyaku: Record Profits Despite Lower Sales
November 25, 2002
- BUSINESS NEWS IN BRIEF
November 25, 2002
- Chugai: Net Loss Due to Merger-related Costs
November 25, 2002
- Abbott Japan to Be Formed on Feb. 2003
November 25, 2002
- Daiichi: Sales, Profits Down from Price Cut Impact on Mainstays
November 25, 2002
- Nippon Kayaku to Make Full Use of Own Unique Technology
November 25, 2002
- Shionogi: Contracting Market Hurts Semiannual Sales, Profits
November 25, 2002
- Over 100 Mil. Prescriptions Issued for Pharmacia's Xalatan
November 18, 2002
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…